Study guide
9.5 High-Frequency MPJE Pitfalls & Distractor Traps
Mississippi MPJE Pharmacy Jurisprudence Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Mississippi MPJE Overview
1.1 Mississippi MPJE Format, Logistics & Official Blueprint 1.2 Study Strategy & Federal vs. Mississippi Legal Hierarchy 1.3 Federal & State Regulatory Authorities & Oversight
2 Chapter 2: Mississippi Pharmacy Governance, Board Structure & Licensure
2.1 Mississippi Board of Pharmacy: Structure, Authority & Operations 2.2 Pharmacist Licensure, Examination, Reciprocity & Continuing Education 2.3 Pharmacy Interns, Externs & Preceptor Requirements 2.4 Pharmacy Technicians: Registration, Scope & Supervision Ratios 2.5 Disciplinary Proceedings, Impairment & Current Monitoring
3 Chapter 3: Pharmacist Practice Standards & Prescribing Authority
3.1 Prescription Requirements, Formats & Electronic Prescribing (EPCS) 3.2 Prescriptive Authority in Mississippi: Physicians, Mid-Level Practitioners & Out-of-State 3.3 Collaborative Drug Therapy Management (CDTM) & Institutional Protocols 3.4 Patient Counseling, Prospective DUR & OBRA '90 Mandates 3.5 HIPAA, Patient Privacy & Confidentiality of Pharmacy Records
4 Chapter 4: Controlled Substances: Scheduling, Ordering & Security
4.1 Federal & Mississippi Controlled Substance Scheduling 4.2 DEA Registration, Mississippi Permitting & Physical Security 4.3 Schedule II Ordering: Single-Sheet DEA Form 222 & Electronic CSOS 4.4 Controlled Substance Inventories: Mississippi Annual Mandate 4.5 Controlled Substance Disposal (DEA Form 41) & Theft/Loss Reporting Protocols
5 Chapter 5: Dispensing Controlled Substances & Prescription Processing
5.1 Schedule II Prescriptions: Issuance, Emergency Oral Dispensing & Sequential Prescriptions 5.2 Partial Filling of Controlled Substances: CARA, Out-of-Stock & Long-Term Care 5.3 Schedule III–V Prescriptions: Refill Limitations, Authorizations & Expirations 5.4 Prescription Transfers: Federal & Mississippi Requirements 5.5 Corresponding Responsibility, Red Flags & Legitimate Medical Purpose
6 Chapter 6: Mississippi Prescription Monitoring Program & Public Health Mandates
6.1 Mississippi Prescription Monitoring Program (MS PMP Gateway): Mandates & 24-Hour Reporting 6.2 Opioid Prescribing Limits, MME Calculations & Acute Pain Restrictions 6.3 Naloxone Standing Order, Overdose Prevention & Harm Reduction Dispensing 6.4 Behind-the-Counter Sales: Pseudoephedrine & Ephedrine Regulations 6.5 Pharmacist Immunization Authority & Protocol Administration in Mississippi
7 Chapter 7: Pharmacy Operations, Permits & Facilities
7.1 Community Pharmacy Permits, Pharmacist-in-Charge (PIC) Duties & Staffing 7.2 Institutional & Hospital Pharmacy Practice Regulations 7.3 Automated Medication Systems, Remote Dispensing & Telepharmacy 7.4 Non-Resident (Mail-Order) Pharmacies, Licensure & Wholesale Distributors 7.5 Drug Supply Chain Security Act (DSCSA), Track-and-Trace & Product Quarantines
8 Chapter 8: Compounding Standards, Safety & Product Selection
8.1 Non-Sterile Compounding (USP <795>): Categories, Beyond-Use Dating & Quality Assurance 8.2 Sterile Compounding (USP <797>): Cleanrooms, ISO Classifications & Aseptic Protocols 8.3 Hazardous Drug Handling (USP <800>): Engineering Controls, PPE & Spill Protocols 8.4 Generic Drug Substitution, FDA Orange Book & Purple Book Biosimilars 8.5 Repackaging, Unit-Dose Beyond-Use Dating & FDA Drug Recall Classifications
9 Chapter 9: Review, Clinical Scenarios & High-Yield Calculations
9.1 High-Yield Scenario Review: Resolving Complex Federal vs. Mississippi Legal Conflicts 9.2 Pharmacy Law Calculations: DEA Verification, Days Supply, Limits & Ratios 9.3 Rapid-Fire Master Review: Key Timelines, Quantities, Retention Periods & Forms 9.4 Exam Day Strategy, Computer-Adaptive Pacing & Distractor Elimination 9.5 High-Frequency MPJE Pitfalls & Distractor Traps
9.5 High-Frequency MPJE Pitfalls & Distractor Traps
Key Takeaways Explain This Topic AI
The highest-risk distractors use formerly common rules: numeric 75 result, 2:1 technicians, 30 biennial CE, no C-II expiration, or one-time controlled refills transfers.
Current Mississippi anchors are 3:1 technicians, 15 annual CE, six-month C-II fill limit, and no controlled-prescription transfers.
Do not collapse loss clocks, PMP reporting/querying, or opioid recommendations: each has a distinct actor and trigger.
Use current 2025–2026 changes: PHN monitoring, March 2, 2026 naloxone order, PSE BTC limits, revised substitution law, and FDA small-dispenser extension.
Current compounding and hazardous-drug standards use revised USP <795>/<797> categories and the two-table NIOSH 2024 list.
Last updated: August 2026
High-Frequency Mississippi MPJE Traps
A strong distractor is often a rule that was once true, is true federally, or is true in another state. Use these current contrasts.
Exam and personnel traps
Result: current candidate report is Pass/Fail, not a scaled 75.
Completion: at least 107 questions for a result; 107–119 incurs a penalty; fewer than 107 yields no result.
Technicians: maximum 3:1 , not 2:1.
CE: 15 hours annually , including at least two live and two opioid-abuse/addiction hours; not 30 biennially or five live hours.
Monitoring: current contractor is PHN , not MARP; do not promise a universal five-year confidential contract.
Controlled-substance traps
C-II expiration: Mississippi does not allow fill after six months ; “no fixed expiration” is false.
C-II emergency: maximum 48-hour supply , signed follow-up in seven days .
C-II partials: patient/prescriber 30 days from issuance; out-of-stock 72 hours from first dispensing; emergency 72 hours from issuance; LTCF/terminal 60 days.
Transfers: Mississippi prohibits transfer of all controlled prescriptions , even where federal law permits a pathway.
Schedule V OTC: qualifying nonprescription sale is allowed only by a pharmacist under 120 cc/4 oz per 72 hours, 2 sales/7 days, 3/30 days, age 18, ID, need, and record safeguards. “All codeine needs a prescription” is false.
Inventory: Article XXV , annual on/about May 1 no later than May 15 or another consistent annual period; alternative date does not require invented Board preapproval.
Records: acquisition two years, disposition six years, disposal two years; not every record six years.
Loss: DEA initial written notice in one business day and Form 106 in 45 days; Board immediate notice, inventory in 48 hours, report in 15 days.
Security: current rules allow authorized access under policy in institutional settings; no blanket pharmacist-only-key claim.
Practice and public-health traps
PMP: report within 24 hours/next business day and submit zero reports; query on the specific new/no-six-month Schedule II opiate trigger and at least every six months for controlled-substance patients.
Opioid acute rule: more than three days discouraged and initial maximum ten days, not a universal seven-day cap. Chronic anchors are 50/90/100 MME.
CDTM: protocol no more than two years and limited to non-scheduled drugs ; no universal annual, consent, or 24-hour requirement in Article XXXVI.
Naloxone: current order effective March 2, 2026 requires approved training, retained documents, legend prescription under issuing physician, and counseling.
PSE: BTC sale is 3.6 g/day and 7.2 g/30 days; stop-sale override only for reasonable fear of imminent bodily harm.
Immunization: current Board Article XXXIV is not a vaccination article; do not rely on unsupported universal ages or course hours.
Operations and federal traps
Community permit: biennial; PIC presence 20 hours or 50%, whichever less.
Institutional timing: after-hours cabinet audit at least monthly, pharmacist review promptly, emergency-kit restock within a reasonable time—not universal 24/48 hours.
Automated systems: prior written notice; no universal legal 24-hour override-review deadline.
Telepharmacy: 15-mile restriction, exactly one certified technician with two years, supervisor max two sites, pharmacist approves every prescription and counsels every new/refill.
Generic/biologic selection: lower purchaser cost, DAW/electronic brand specification, purchaser choice, G.E./I.B.; former five-day biosimilar notice removed.
DSCSA: current exchange is TI/TS, not all three Ts; qualifying small-dispenser enhanced-security exemption extends through November 27, 2027.
USP <795>: no simple/moderate/complex categories; current 14/35/90/180-day defaults.
USP <797>: Category 1 is 12 hours room/24 refrigerated.
NIOSH: 2024 list uses two tables, not three groups.
Waste: bin color alone does not establish legal hazardous-waste classification.
Elimination technique
Attach each number to its noun and verb. “48 hours” could mean emergency C-II quantity, loss inventory, or PMP reporting exclusion. “Six months” could mean prescription lifespan or PMP query lookback. An option with the right number but wrong event is wrong.
Finally, distinguish legal requirement , authorized option , recommendation , and pharmacy policy . Many authoring errors come from converting “should” or prudent workflow into “must within exactly X hours.”
Last-pass check
For every memorized contrast, retain the source label: Board Article XV—no controlled transfers; Article XVIII—eligible Schedule V nonprescription sale; Article XXV—inventory and loss; Article XLIII—PMP; § 73-21-117—selection. Source labels make similar numbers easier to reconstruct and reveal answer choices built from the wrong article.